56 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
16
Ending by 2030
Jan 2027
Next term end
29
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2030 · High confidence
Also notable
Ends no later than Oct 2031 · Low confidence
Also notable
Ends Sep 2027 · High confidence
Isolation of Adult Multipotential Cells by Tissue Non-Specific Alkaline Phosphatase
US 8,367,405
The most cited patent in this portfolio, cited by 87 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2030.
Enhanced MSC Preparations
US 9,963,678
Cited by 43 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Mesenchymal Stem Cells Expressing TNF-alpha Receptors
US 11,821,004
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Cell Culture Method for Mesenchymal Stem Cells (US 11,685,899) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Method for Treating Heart Failure (US 11,712,452) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Improved Stem Cell Composition (US 10,400,218) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 2 fees due Apr 24 to 29, 2027 · next Apr 24
- 2 fees due Aug 4 to 23, 2027 · next Aug 4
- 1 fee due Sep 24, 2027The maintenance fee for Methods of Treating or Preventing Rheumatic Disease (US 10,596,199) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 3 fees due Oct 5 to 21, 2027 · next Oct 5
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 1 term has ended since Aug 16, 2026
What they patent
The 5 largest of its 29 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Enhanced MSC Preparations | 5 in force | to Jan 2032 |
| Treatment of Immune Disorders | 4 in force | to Apr 2036 |
| Methods of Treating or Preventing Rheumatic Disease | 3 in force | to Jul 2032 |
| Method of Treating Graft Versus Host Disease | 3 in force | to Jan 2032 |
| Method for Treating or Preventing a Pancreatic Dysfunction | 3 in force | to Oct 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,486,695 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors held by Mesoblast International Sàrl In force · High confidence | In force | High confidence | |
| US 11,821,004 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors held by Mesoblast International Sàrl In force · High confidence | In force | High confidence | |
| US 7,696,309 | Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage held by Mesoblast International Sàrl In force · High confidence | In force | High confidence | |
| US 7,999,067 | Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage held by Mesoblast International Sàrl In force · High confidence | In force | High confidence | |
| US 12,220,433 | Methods of Generating, Repairing And/Or Maintaining Connective Tissue in Vivo In force · High confidence | In force | High confidence | |
| US 12,275,801 | Isolation of Adult Multipotential Cells by Tissue Non-Specific Alkaline Phosphatase In force · High confidence | In force | High confidence | |
| US 8,858,932 | Repair And/Or Reconstitution of Invertebral Discs In force · High confidence | In force | High confidence | |
| US 12,558,382 | Repair And/Or Reconstruction of Invertebral Discs In force · High confidence | In force | High confidence | |
| US 9,815,896 | Monoclonal Antibody STRO-4 In force · High confidence | In force | High confidence | |
| US 8,828,375 | Expansion of Haemopoietic Precursors In force · High confidence | In force | High confidence |
Also on record, not counted in the 56: 38 patents ended · 40 applications pending · 71 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.